A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Quilizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SOLARIO
  • Sponsors Genentech
  • Most Recent Events

    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
    • 20 May 2012 Status changed from active, no longer recruiting to completed based on results being reported at the 108th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top